Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CV Therapeutics has reported that Ranexa reduced the relative risk of the primary composite endpoint of cardiovascular death, myocardial infarction or recurrent ischemia by 21% compared to placebo in 1,935 patients with an elevated level of b-type natriuretic peptide in the Merlin Timi-36 study.
Subscribe to our email newsletter
The data was presented by Dr. David Morrow of the Timi Study Group at the American Heart Association Scientific Sessions in Orlando, Florida.
Ranexa (ranolazine) is believed to exert its anti-ischemic effects through ion channel activity which may ultimately reduce left ventricular (LV) wall stress and improve diastolic dysfunction and b-type natriuretic peptide (BNP) rises in response to LV wall stress and is a potent indicator of risk in acute coronary syndromes (ACS).
Dr David Morrow of the Timi Study Group, said: “The potential enhanced efficacy of ranolazine in patients with elevated BNP in this analysis is consistent with the drug’s mechanism of action. Elevated BNP is among the most powerful indicators of risk for ACS patients, and it is very intriguing to see the potentially beneficial effects of ranolazine in this group of MERLIN TIMI-36 patients. Few interventions have been shown to modify the risk associated with increased BNP. This finding warrants prospective confirmation.”